| Chronic Obstructive Airway Disease
Advair Diskus vs Anoro Ellipta
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Advair vs Anoro Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAnoro Ellipta has a higher rate of injection site reactions vs Advair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Anoro Ellipta but not Advair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair
Anoro Ellipta
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Once daily
LAMA/LABA
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Asthma 1 inhalation twice daily approximately 12 hours apart; adults and adolescents aged >=12 years may use 100/50, 250/50, or 500/50 strengths (max ADVAIR DISKUS 500/50 twice daily); pediatric patients aged 4 to 11 years use 1 inhalation of ADVAIR DISKUS 100/50 twice daily.
Chronic Obstructive Airway Disease 1 inhalation of ADVAIR DISKUS 250/50 twice daily approximately 12 hours apart.
Chronic Obstructive Airway Disease 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of ANORO ELLIPTA 62.5/25 mcg) once daily by oral inhalation; do not use more than 1 time every 24 hours.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to umeclidinium, vilanterol, or any excipient
- Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) in patients with asthma
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, pharyngitis, headaches, candidiasis mouth/throat, throat irritation, hoarseness/dysphonia, musculoskeletal pain, viral respiratory infections, nausea and vomiting, bronchitis, sinusitis, dizziness, muscle cramps and spasms
Serious Serious asthma-related events (hospitalizations, intubations, death), pneumonia in patients with COPD, cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma and cataracts
Postmarketing Arrhythmias (including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia), Cushing's syndrome, glaucoma, hyperglycemia, osteoporosis, paradoxical bronchospasm, immediate and delayed hypersensitivity reactions including anaphylaxis, agitation, depression, dysmenorrhea
Most common (>=1%) Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain
Serious Serious asthma-related events (hospitalizations, intubations, death), paradoxical bronchospasm, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, increased intraocular pressure, anaphylaxis, angioedema, urticaria, dysgeusia, tremor, anxiety, dysuria, urinary retention, dysphonia
Pharmacology
ADVAIR DISKUS combines fluticasone propionate, a synthetic trifluorinated corticosteroid that suppresses airway inflammation by acting on multiple cell types and mediators, and salmeterol, a selective long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Umeclidinium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors in airway smooth muscle to produce bronchodilation; vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Anoro Ellipta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Advair
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Anoro Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Advair
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (3/3)
Anoro Ellipta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair.
No savings programs available for Anoro Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdvairView full Advair profile
Anoro ElliptaView full Anoro Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.